<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03583359</url>
  </required_header>
  <id_info>
    <org_study_id>M900391004</org_study_id>
    <nct_id>NCT03583359</nct_id>
  </id_info>
  <brief_title>Evaluation of Effectiveness and Safety of Radiesse (+) to Improve the Contour of Jawline by Adding Volume to the Jawline</brief_title>
  <official_title>Evaluation of Effectiveness and Safety of Radiesse (+) to Improve the Contour of Jawline by Adding Volume to the Jawline</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz North America, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the effectiveness and safety of Radiesse (+) following deep (subdermal and/or
      supraperiosteal) injection to improve the contour of jawline by adding volume to the jawline.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 8, 2018</start_date>
  <completion_date type="Actual">March 27, 2020</completion_date>
  <primary_completion_date type="Actual">May 22, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the responder rate between the treatment group and the untreated control group at Week 12, according to the Merz Jawline Assessment Scale (MJAS)</measure>
    <time_frame>Week 12</time_frame>
    <description>The MJAS is a 5-point scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Descriptive summary of the FACE-Q satisfaction of the lower face and jawline for treated subjects at baseline and Week 12.</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average percent change of the FACE-Q from baseline to Week 12</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Descriptive summary of Global Aesthetic Improvement Scale (GAIS) scores for treated subjects at Week 12, as completed by the treating investigator.</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Descriptive summary of Global Aesthetic Improvement Scale (GAIS) scores for treated subjects at Week 12, as completed by the subject.</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Descriptive summary of the responder rates in the treatment group and the untreated control group at Week 12, according to the Merz Jawline Assessment Scale (MJAS).</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Improvement of Jawline Contour</condition>
  <arm_group>
    <arm_group_label>Treatment with Radiesse (+)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrolled subjects will be randomized (2:1 allocation ratio) to either receive treatment with Radiesse (+) or delayed treatment with Radiesse (+).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed Treatment with Radiesse (+)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Enrolled subjects will be randomized (2:1 allocation ratio) to either receive treatment with Radiesse (+) or delayed treatment with Radiesse (+).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Radiesse (+)</intervention_name>
    <description>Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier with 3% lidocaine hydrochloride (HCl).
Mode of application: intradermal and/or supraperiosteal injection in the jaw Region. Treated subjects will receive a maximum volume of 3.0 cc of Radiesse (+) per jawline during the initial injection and at the optional Week 48 re-treatment, and 1.5cc per jawline during the optional touch-up.</description>
    <arm_group_label>Delayed Treatment with Radiesse (+)</arm_group_label>
    <arm_group_label>Treatment with Radiesse (+)</arm_group_label>
    <other_name>Radiesse® Injectable Dermal Filler with Lidocaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Has right and left jawline ratings of 2 or 3 (moderate or severe) on the MJAS, as
             determined independently by the blinded evaluator and the treating investigator.

          2. Has the same MJAS score on both jawlines (i.e., jawlines are symmetrical).

          3. Is ≥22 and ≤65 years of age.

          4. Has adequate understanding (reading, speaking and writing) of the local/regional
             language.

        Exclusion Criteria:

          1. Skin or fat atrophy, other than age related, in the midfacial and/or jawline region or
             has been diagnosed with a connective tissue disorder.

          2. Skin laxity and/or sun damage beyond typical for the subject's age.

          3. Prior surgery on the jaw or in the jawline area (including temporomandibular joint
             replacement or anatomical surgical modification) or has a permanent implant or graft
             in the lower face and/or jawline area that could interfere with effectiveness
             assessments

          4. Ever been treated with fat injections or permanent fillers (e.g., silicone,
             polymethylmethacrylate (PMMA)) in the lower face and/or jawline area or plans to
             receive such treatments during participation in the study.

          5. Been treated with semi-permanent dermal fillers (e.g., poly L-lactic acid) in the
             lower face and/or jawline area in the past 5 years or plans to receive such treatments
             during participation in the study.

          6. Received lower face and/or jawline area treatments with porcine-based collagen fillers
             or with Belotero® Volume, JUVÉDERM VOLUMA®, Restylane® Lyft, RADIESSE®, or mesotherapy
             within the past 24 months and/or with other hyaluronic acid (HA) products within the
             past 12 months or plans to receive such treatments during participation in the study.

          7. Undergone oral surgery (e.g., orthodontia, extraction, implants) in the past 30 days
             or plans to undergo oral surgery during participation in the study.

          8. Subjects with any malocclusion(s) that are unstable and/or not reproducible or
             active/history of lockjaw.

          9. Subjects with body mass index (BMI) of &lt; 18.5 or ≥ 30.

         10. Subjects who have gained or lost significant weight over the past 6 months (i.e. ≥
             2-unit change in BMI); or subjects who plan to gain or lose significant weight during
             study participation (i.e. ≥ 2-unit change in BMI).

         11. Subjects with jawline contour that is masked and/or difficult to differentiate from
             the neck due to submental fat pad(s), significant neck lipodystrophy, and/or neck skin
             redundancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merz Medical Expert</last_name>
    <role>Study Director</role>
    <affiliation>Merz North America, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Testing of Beverly Hills, Merz Investigational Site #0010395</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Care Center, Merz Investigational Site #0010099</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ava MD, Merz Investigational Site #0010299</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moradi MD Face Beautiful Inc, Merz Investigational Site #0010358</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AboutSkin Research LLC, Merz Investigational Site #0010103</name>
      <address>
        <city>Greenwood Village</city>
        <state>Colorado</state>
        <zip>80111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Skin Research Institute, Merz Investigational Site #0010101</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of the Southeast, LLC, Merz Investigational Site #0010420</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lupo Center for Aesthetic and General Dermatology, Merz Investigational Site #0010418</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Laser Skin &amp; Vein Institute, Merz Investigational Site #0010323</name>
      <address>
        <city>Hunt Valley</city>
        <state>Maryland</state>
        <zip>21030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SkinCare Physicians of Chestnut Hill. Merz Investigational #0010098</name>
      <address>
        <city>Chestnut Hill</city>
        <state>Massachusetts</state>
        <zip>02467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skinfluence Medical PC, Merz Investigational #0010421</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bass Plastic Surgery PLLC, Merz Investigational Site #0010419</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology, Laser &amp; Vein Specialists of the Carolinas, Merz Investigational Site #0010194</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of the Carolinas, Merz Investigational Site #0010417</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westlake Dermatology, Merz Investigational Site #0010322</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78746</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 28, 2018</study_first_submitted>
  <study_first_submitted_qc>June 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2018</study_first_posted>
  <disposition_first_submitted>May 15, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>May 15, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 19, 2020</disposition_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

